nivolumab plus ipilimumab
Double Checkpoint Inhibitors Plus TKI Improves Control of RCC
In patients with advanced renal cell carcinoma, the addition of the tyrosine kinase inhibitor cabozantinib ...
OCTOBER 3, 2022
Nivolumab-Ipilimumab Combo Approved to Treat Previously Treated HCC
The FDA granted accelerated approval for the use of nivolumab plus ipilimumab to treat hepatocellular carcinoma in ...
MARCH 12, 2020
Load more